Early Access to orphan drugs has seen recent activity in the last few months in the form of legislation, from the UK’s Early Access to Medicines Scheme (EAMS) to the EMA’s Adaptive Licencing pilot. In light of the ongoing changes and new developments, we have spoken with Dr Geoffrey Guy, Founder and Chairman of GW Pharmaceuticals on EAMS and some of the challenges that it might face in the sector.
This report discusses:
– The global market for fast tracking orphan drugs
– The Early Access to Medicines Scheme
– What five things the UK can learn from the US early access schemes
To learn more about the topics above download a copy today!
Geoffrey will be participating at the upcoming Fast Tracking Orphan Drugs Briefing on 10th July in London.